{"entity":{"type":"insider","cik":"0001767396","url":"/insider/0001767396","json_url":"/insider/0001767396.json","name":"F2 MG Ltd","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":38,"n_filings":6,"first":"2019-02-21","last":"2021-01-14","span_basis":"filed_date"},"name_variants":[{"name":"F2 MG Ltd","source":"filing","n_filings":6,"first_seen":"2019-02-21","last_seen":"2021-01-14"}],"transactions":[{"id":4083654,"accession":"0000899243-21-002048","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0000899243-21-002048","line_url":"/filing/0000899243-21-002048","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"Cullinan Management, Inc.","issuer_ticker":"CGEM","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"F2 - TPO Investments LLC; Jovan-Embiricos Morana; F2 MG Ltd; Globeways Holdings Ltd; F2 Bioscience I 2017 Ltd; F2 MC, LLC; F2 Bio TD, LLC; F2 Vision SCS; F2 GC, LLC","owner_display_name":"F2 - TPO Investments LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":21.0,"price_display":"21.00","price_state":"stated","total_value":4200000.0,"total_display":"4,200,000.00","total_whole":"4,200,000","shares_owned_after":104762.0,"shares_owned_after_display":"104,762","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-01-12","filed_date":"2021-01-14","scope":"insider","n_lines":2},{"id":8725355,"accession":"0000899243-19-029791","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-029791","line_url":"/filing/0000899243-19-029791","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"F2 - TPO Investments LLC; F2 Capital I 2019, LLC; F2 BBG LLC; Jovan-Embiricos Morana; F2 MG Ltd; Globeways Holdings II Ltd; F2 Capital I 2015 Ltd; Globeways Holdings Ltd; F2 Captial I 2017 Ltd; F2 Bioscience II 2017 Ltd","owner_display_name":"F2 - TPO Investments LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":41965.0,"shares_display":"41,965","price_per_share":16.4714,"price_display":"16.47","price_state":"stated","total_value":691222.301,"total_display":"691,222.30","total_whole":"691,222","shares_owned_after":155986.0,"shares_owned_after_display":"155,986","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-19","filed_date":"2019-12-20","scope":"insider","n_lines":2},{"id":8725350,"accession":"0000899243-19-029791","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-19-029791","line_url":"/filing/0000899243-19-029791","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"F2 - TPO Investments LLC; F2 Capital I 2019, LLC; F2 BBG LLC; Jovan-Embiricos Morana; F2 MG Ltd; Globeways Holdings II Ltd; F2 Capital I 2015 Ltd; Globeways Holdings Ltd; F2 Captial I 2017 Ltd; F2 Bioscience II 2017 Ltd","owner_display_name":"F2 - TPO Investments LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2891.0,"shares_display":"2,891","price_per_share":17.006,"price_display":"17.01","price_state":"stated","total_value":49164.346,"total_display":"49,164.35","total_whole":"49,164","shares_owned_after":191309.0,"shares_owned_after_display":"191,309","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-18","filed_date":"2019-12-20","scope":"insider","n_lines":2},{"id":7886918,"accession":"0000899243-19-028968","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000899243-19-028968","line_url":"/filing/0000899243-19-028968","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"Globeways Holdings Ltd; F2 MG Ltd; Jovan-Embiricos Morana; F2 - TPO Investments LLC; F2 Capital I 2015 Ltd; F2 Captial I 2017 Ltd; Globeways Holdings II Ltd","owner_display_name":"Globeways Holdings Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7743.0,"shares_display":"7,743","price_per_share":17.6525,"price_display":"17.65","price_state":"stated","total_value":136683.3075,"total_display":"136,683.31","total_whole":"136,683","shares_owned_after":1299876.0,"shares_owned_after_display":"1,299,876","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-11","filed_date":"2019-12-11","scope":"insider","n_lines":4},{"id":7886902,"accession":"0000899243-19-028968","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000899243-19-028968","line_url":"/filing/0000899243-19-028968","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"Globeways Holdings Ltd; F2 MG Ltd; Jovan-Embiricos Morana; F2 - TPO Investments LLC; F2 Capital I 2015 Ltd; F2 Captial I 2017 Ltd; Globeways Holdings II Ltd","owner_display_name":"Globeways Holdings Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":56830.0,"shares_display":"56,830","price_per_share":17.6232,"price_display":"17.62","price_state":"stated","total_value":1001526.456,"total_display":"1,001,526.46","total_whole":"1,001,526","shares_owned_after":1304029.0,"shares_owned_after_display":"1,304,029","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-10","filed_date":"2019-12-11","scope":"insider","n_lines":4},{"id":7886888,"accession":"0000899243-19-028968","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-028968","line_url":"/filing/0000899243-19-028968","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"Globeways Holdings Ltd; F2 MG Ltd; Jovan-Embiricos Morana; F2 - TPO Investments LLC; F2 Capital I 2015 Ltd; F2 Captial I 2017 Ltd; Globeways Holdings II Ltd","owner_display_name":"Globeways Holdings Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":139989.0,"shares_display":"139,989","price_per_share":17.6511,"price_display":"17.65","price_state":"stated","total_value":2470959.8379,"total_display":"2,470,959.84","total_whole":"2,470,960","shares_owned_after":1334504.0,"shares_owned_after_display":"1,334,504","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-12-09","filed_date":"2019-12-11","scope":"insider","n_lines":4},{"id":8580892,"accession":"0000899243-19-025909","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-19-025909","line_url":"/filing/0000899243-19-025909","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"F2 MG Ltd; Jovan-Embiricos Morana; F2 Capital I 2015 Ltd; F2 Captial I 2017 Ltd; Globeways Holdings Ltd; Globeways Holdings II Ltd; F2 - TPO Investments LLC","owner_display_name":"F2 MG Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3888.0,"shares_display":"3,888","price_per_share":15.1571,"price_display":"15.16","price_state":"stated","total_value":58930.8048,"total_display":"58,930.80","total_whole":"58,931","shares_owned_after":1409571.0,"shares_owned_after_display":"1,409,571","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-10-22","filed_date":"2019-10-24","scope":"insider","n_lines":4},{"id":8197830,"accession":"0000899243-19-024208","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000899243-19-024208","line_url":"/filing/0000899243-19-024208","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"Globeways Holdings II Ltd; F2 BBG LLC; F2 MG Ltd; Globeways Holdings Ltd; F2 Capital I 2019, LLC; F2 - TPO Investments LLC; F2 Capital I 2015 Ltd; F2 Captial I 2017 Ltd; Jovan-Embiricos Morana","owner_display_name":"Globeways Holdings II Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11321.0,"shares_display":"11,321","price_per_share":17.3114,"price_display":"17.31","price_state":"stated","total_value":195982.3594,"total_display":"195,982.36","total_whole":"195,982","shares_owned_after":1411656.0,"shares_owned_after_display":"1,411,656","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-09-23","filed_date":"2019-09-24","scope":"insider","n_lines":6},{"id":8197804,"accession":"0000899243-19-024208","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-19-024208","line_url":"/filing/0000899243-19-024208","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"Globeways Holdings II Ltd; F2 BBG LLC; F2 MG Ltd; Globeways Holdings Ltd; F2 Capital I 2019, LLC; F2 - TPO Investments LLC; F2 Capital I 2015 Ltd; F2 Captial I 2017 Ltd; Jovan-Embiricos Morana","owner_display_name":"Globeways Holdings II Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":405000.0,"shares_display":"405,000","price_per_share":17.9354,"price_display":"17.94","price_state":"stated","total_value":7263837.0,"total_display":"7,263,837.00","total_whole":"7,263,837","shares_owned_after":1417172.0,"shares_owned_after_display":"1,417,172","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-09-20","filed_date":"2019-09-24","scope":"insider","n_lines":6},{"id":8502390,"accession":"0000899243-19-004404","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000899243-19-004404","line_url":"/filing/0000899243-19-004404","is_derivative":false,"issuer_cik":"0001575745","issuer_name":"TCR2 THERAPEUTICS INC.","issuer_ticker":"TCRR","issuer_name_source":null,"issuer_url":"/issuer/0001575745","owner_cik":null,"owner_name":"Globeways Holdings II Ltd; F2 BBG LLC; F2 Bioscience II 2017 Ltd; F2 - TPO Investments LLC; F2 Capital I 2019, LLC; Globeways Holdings Ltd; F2 Captial I 2017 Ltd; F2 Capital I 2015 Ltd; F2 MG Ltd; Jovan-Embiricos Morana","owner_display_name":"Globeways Holdings II Ltd","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":666667.0,"shares_display":"666,667","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":10000005.0,"total_display":"10,000,005.00","total_whole":"10,000,005","shares_owned_after":200000.0,"shares_owned_after_display":"200,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-19","filed_date":"2019-02-21","scope":"insider","n_lines":4}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001789972","name":"Cullinan Management, Inc.","url":"/issuer/0001789972","role":"Ten percent owner","n_filings":1,"first_seen":"2021-01-14","last_seen":"2021-01-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001750019","name":"TCR2 THERAPEUTICS INC.","url":"/issuer/0001750019","role":"Ten percent owner","n_filings":5,"first_seen":"2019-02-21","last_seen":"2019-12-20"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001767396","retrieved_at":"2026-08-23T14:12:13+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}